Investment firms Highland Capital Management and Coatue led a $235m funding round in Caris Life Sciences, an innovator in molecular science, with participation from T. Rowe Price Associates, OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors. "This financing represents the first significant external equity investment in Caris. We are tremendously proud to partner with a diverse and high-quality syndicate of leading investors with deep domain knowledge in healthcare and technology," Brian J. Brille, Caris Vice Chairman.